Last updated: 2026-09-16 11:04:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Vogenx Inc. (VOGX) operates in the -- sector and is listed on NASDAQ. The stock is currently priced at $32.66, with a market capitalisation of $481.60M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $12.95 to $35.50. This page covers its latest market performance, valuation, price trends and company information.
$481.60M | |
$32.53 | |
$35.50 | |
$12.95 | |
$32.42 | |
148.31K | |
220.94K | |
-- | |
$35.50 | |
$12.95 | |
-- | |
-- |
Vogenx Inc. (VOGX) is trading at $32.42 in pre-market trading as of 2026-09-15 23:31:00, unchanged from the previous close of $32.42
Pre-market trading shows how investors are pricing VOGX before the regular session opens. The current pre-market price is near the previous close, indicating neutral early trading sentiment.
Over the past seven days, Vogenx Inc. (VOGX) moved from $31.73 to $32.66, representing a gain of 2.92% ($0.93).
The stock traded between $28.55 and $34.13 during the period. The latest price is near the upper end of the 7-day range, indicating moderate upward.
The average daily volume was 128.95 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 87.4%
VOGX is currently trading at $32.66, placing it 87.4% of the way from its 52-week low of $12.95 to its 52-week high of $35.50. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Vogenx Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia, or PBH, and gastroparesis. The company's flagship product candidate, mizagliflozin, is an orally administered, minimally absorbed, small molecule drug candidate being developed for the treatment of post-bariatric hypoglycemia (PBH), gastroparesis and GIP-induced Cushing's Syndrome. It operates as a single reportable segment engaged in the discovery and development of treatments for serious metabolic and gastrointestinal diseases.
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Vogenx Inc. (VOGX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.